Wellgistics Health Eyes $105M All-Stock Acquisition of Neuritek, Dwarfing Its Market Cap Amid Going Concern Warning
WGRX sits 24% above its 52-week low of $0.108.
Summary
Wellgistics Health Inc. has signed a non-exclusive, non-binding Letter of Intent (LOI) to evaluate a potential $105 million all-stock acquisition of Neuritek Therapeutics, Inc., a private company focused on neurological and psychiatric therapies. This proposed transaction is highly material, as the $105 million valuation is approximately 8.5 times Wellgistics' current market capitalization of roughly $12.3 million. The announcement comes just three days after Wellgistics' 10-K filing, which disclosed a "going concern" warning, a Nasdaq delisting notice, an auditor resignation, and a $101 million net loss. While the LOI is non-binding, the intent to pursue such a massively dilutive transaction, especially for a company in severe financial distress, introduces extreme uncertainty and risk for shareholders. Traders will closely monitor any progress on due diligence, definitive agreements, and the feasibility of this deal given Wellgistics' precarious financial state and delisting threat.
At the time of this announcement, WGRX was trading at $0.13 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $12.3M. The 52-week trading range was $0.11 to $7.04. This news item was assessed with neutral market sentiment and an importance score of 9 out of 10. Source: Access Newswire.